- Home
- TUSK vs AGEN Comparison
TUSK vs AGEN Comparison
Compare TUSK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TUSK
- AGEN
- Stock Information
- Founded
- TUSK 2014
- AGEN 1994
- Country
- TUSK United States
- AGEN United States
- Employees
- TUSK N/A
- AGEN N/A
- Industry
- TUSK Oilfield Services/Equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TUSK Energy
- AGEN Health Care
- Exchange
- TUSK Nasdaq
- AGEN Nasdaq
- Market Cap
- TUSK 131.4M
- AGEN 142.8M
- IPO Year
- TUSK 2016
- AGEN 2000
- Fundamental
- Price
- TUSK $2.37
- AGEN $4.56
- Analyst Decision
- TUSK
- AGEN Buy
- Analyst Count
- TUSK 0
- AGEN 2
- Target Price
- TUSK N/A
- AGEN $14.50
- AVG Volume (30 Days)
- TUSK 76.0K
- AGEN 387.3K
- Earning Date
- TUSK 10-31-2025
- AGEN 11-11-2025
- Dividend Yield
- TUSK N/A
- AGEN N/A
- EPS Growth
- TUSK N/A
- AGEN N/A
- EPS
- TUSK N/A
- AGEN N/A
- Revenue
- TUSK $188,567,000.00
- AGEN $101,706,000.00
- Revenue This Year
- TUSK N/A
- AGEN $60.49
- Revenue Next Year
- TUSK $28.22
- AGEN N/A
- P/E Ratio
- TUSK N/A
- AGEN N/A
- Revenue Growth
- TUSK 26.46
- AGEN N/A
- 52 Week Low
- TUSK $1.68
- AGEN $1.38
- 52 Week High
- TUSK $4.90
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- TUSK 49.26
- AGEN 48.66
- Support Level
- TUSK $2.29
- AGEN $4.36
- Resistance Level
- TUSK $2.37
- AGEN $5.20
- Average True Range (ATR)
- TUSK 0.07
- AGEN 0.27
- MACD
- TUSK 0.01
- AGEN 0.05
- Stochastic Oscillator
- TUSK 65.62
- AGEN 43.18
About TUSK Mammoth Energy Services Inc.
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes well completion services (Well Completion), infrastructure services (Infrastructure) and natural sand proppant services (Sand). Key revenue is generated from Infrastructure which include electric utility infrastructure services to government-funded utilities, private utilities, public investor-owned utilities, etc.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).